MacroGenics Operating Margin from 2010 to 2024
| MGNX Stock | USD 3.24 0.03 0.93% |
Check MacroGenics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MacroGenics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.3 M, Interest Expense of 1.5 M or Selling General Administrative of 37 M, as well as many indicators such as Price To Sales Ratio of 9.98, Dividend Yield of 0.0 or PTB Ratio of 4.1. MacroGenics financial statements analysis is a perfect complement when working with MacroGenics Valuation or Volatility modules.
MacroGenics | Operating Margin |
Latest MacroGenics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of MacroGenics over the last few years. It is MacroGenics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MacroGenics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.49 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
MacroGenics Operating Margin Regression Statistics
| Arithmetic Mean | (1.17) | |
| Coefficient Of Variation | (107.18) | |
| Mean Deviation | 1.10 | |
| Median | (0.80) | |
| Standard Deviation | 1.26 | |
| Sample Variance | 1.58 | |
| Range | 3.0013 | |
| R-Value | (0.79) | |
| Mean Square Error | 0.64 | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | (0.22) | |
| Total Sum of Squares | 22.11 |
MacroGenics Operating Margin History
About MacroGenics Financial Statements
MacroGenics investors use historical fundamental indicators, such as MacroGenics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MacroGenics. Please read more on our technical analysis and fundamental analysis pages.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 427 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.